 |
 |
Rasagiline is similar to seligine (e.g. Eldepryl) but without the side effects AND a greater likelihood of neuroprotection (i.e. stopping the degeneration of the dopamine-producing cells of the brain). It was developed by Teva Pharmaceuticals, Israel's largest pharm. co. It has been around since at least 1998, has been accepted by a number of countries, and is just beginning phase III clinical trials at a number of sites in the US. The site I will work with is Duke University Medical Center. The lead site is in Philadelphia, I think (today I spoke with a research nurse who mentioned that the Duke team had just returned from a meeting in Philadelphia). The clinical description of rasagiline is that it is "a potent and irreversible inhibitor of the enzyme, monoamine oxide type B, MAO-B, which contributes to the breakdown of dopamine." Could any MDs or research scientists on the list elaborate on this? Does the fact that it is "irreversible" make it risky" Some web sites with more info. include: http://www.tevapharm.com/pr/2000/pr_236.html http://www.lundbeck.com/Newsroom/pressreleases/show.asp?ID=47 http://www.parkinson.org/texthtms/tpddstud.htm Rees Jenkins ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn